Verrucae vulgaris, or common warts, is a common skin condition with no US Food and Drug Administration-approved treatment.

VP-102 is a proprietary drug-device combination product containing a topical formulation of cantharidin (0.7% w/v) in a proprietary single-use applicator that is under investigation for the treatment of common warts.

VP-102 under occlusion showed efficacy in complete clearance of common warts from baseline to day 84, as well as at follow-up visits out to day 147. The most common adverse effects were expected, including application site reactions, and were mild to moderate in severity.

These positive findings warrant future trials to establish the safety and efficacy of VP-102 under occlusion in a larger population of patients with common warts.